As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 28, 2026 at 4:00 PM to consider, among others, annual audited financial statements of the Company for the year ended June 30, 2026.

Refer to their earlier news disseminated by DSE on 07.10.2026 regarding clarification on recent news published in the online news and further query issued by DSE on October 13, 2026, the company has further informed, among others, the following: "...We did not publish a separate dissemination notification. This omission was purely unintentional. Mentionable that Our company primarily manufactures and supplies pharmaceutical items, specifically contraceptive (birth control) products, which are historically sold through government tender processes. Over the last two years, sales through government tenders were temporarily halted, which severely impacted our cash flow and led to a delay in servicing our bank loan interest. Of the total interest amount of BDT 21.78 Crore, we have repaid BDT 8.80 Crore, leaving an overdue balance of BDT 12.98 Crore. Furthermore, we were unaware that the bank had initiated the auction process at that stage..."

In response to a DSE query letter dated October 06, 2026 regarding a news published in an online news titled "Techno Drugs' main factory up for auction, Tk. 203 crore in loan default (translated from Bengali to English)" on October 05, 2026, the company has informed the following: "Our company operates two manufacturing facilities located in Gazipur and Narsingdi. A significant portion of our manufactured (cont.1) medicines specifically Contraceptive (Birth Control) products has historically been sold through government tender processes. In the previous year, sales through Government tenders were temporarily halted, which adversely impacted the company's expected cash flow. As a consequence, there was a temporary delay in servicing our regular bank loan installments. Due to the delay in installment payments, the respective bank issued a notice, which (cont.2) was recently published in Daily Samakal. Please be informed that the management takes this matter with utmost seriousness. We are actively engaged in advanced bilateral negotiations with the bank to resolve the issue through by pay Cheque for loan Adjustment. (cont.3) Production activities across our factories remain operational. We anticipate that once the tender process resumes, the company's revenue stream and banking operations will swiftly normalize. We assure our valued shareholders, investors, and the DSE authorities that the management is taking all necessary and effective steps to resolve this temporary loan-related challenge at the earliest."

Techno Drugs Limited submitted auditor's report regarding status of IPO (Initial Public Offering) Proceeds utilization statement for the Quarter ended on 30 June 2026. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/Techno%20Drugs826.pdf

Emerging Credit Rating Limited (ECRL) has assigned Surveillance rating of the Company as "BBB" in the long term and "ST-3" in the short term along with a Stable outlook based on audited financial statements up to June 30, 2025, quarterly unaudited financial statement up to March 31, 2026, and other relevant quantitative as well as qualitative information up to the date of rating.

Trading of the shares of the company will resume on 11.06.2026.

Trading of the shares of the company will remain suspended on record date i.e., 10.06.2026 for EGM.

Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle from 08.06.2026 to 9.06.2026 and trading of the shares will remain suspended on record date i.e., 10.06.2026 for EGM.

Techno Drugs Limited submitted auditor's report regarding status of IPO (Initial Public Offering) Proceeds utilization statement for the quarter ended 31 March, 2026. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/Techno%20Drugs%20Limited26.pdf

The company has informed that the Board of Directors of the company in its 196th Meeting held on May 14, 2026 has decided to issue 25% Redeemable and 75% Convertible Coupon Bearing Bond of BDT 50.00 crore for 5 years to restructuring the company's loans subject to the approval from the shareholders of the Company in EGM and the approval from Bangladesh Securities and Exchange Commission (BSEC). Date of EGM: June 24, 2026 at 11.00 a.m. Record Date for EGM: June 10, 2026. Venue: Using Hybrid System in combination of Digital Platform through the link https://technodrug.hybridegmbd.net and Physical Presence at Institution of Diploma Engineers, 160/A, Kakrail VIP Road, Dhaka 1000. The Board of Directors has also decided to appoint MTB Capital Limited as the Issue Manager and Arranger for the proposed transaction.